ethosuximide has been researched along with valganciclovir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Burghardt, NS; Denny, CA; Drew, LJ; Friedman, D; Hen, R; Hsieh, J; Iyengar, SS; LaFrancois, JJ; Scharfman, HE; Wu, MV | 1 |
1 review(s) available for ethosuximide and valganciclovir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for ethosuximide and valganciclovir
| Article | Year |
|---|---|
Suppression of adult neurogenesis increases the acute effects of kainic acid.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Doublecortin Domain Proteins; Electroencephalography; Ethosuximide; Excitatory Amino Acid Agonists; Ganciclovir; Glial Fibrillary Acidic Protein; Hippocampus; Kainic Acid; Male; Mice; Mice, Inbred C57BL; Microtubule-Associated Proteins; Neural Stem Cells; Neurogenesis; Neuropeptides; Seizures; Thymidine Kinase; Valganciclovir; X-Rays | 2015 |